HOLX Quote, Financials, Valuation and Earnings

Nuwellis has a net margin of 19.67% compared to Hologic's net margin of -63.22%. Hologic's return on equity of 15.28% beat Nuwellis's return on equity of -800.59%.

Hologic has a consensus price target of $78.66, signalling upside risk potential of 27.09%. On the other hand Nuwellis has an analysts' consensus of $13.00 which suggests that it could grow by 1040.35%. Given that Nuwellis has higher upside potential than Hologic, analysts believe Nuwellis is more attractive than Hologic.

Hologic has a beta of 0.971, which suggesting that the stock is 2.862% less volatile than S&P 500. In comparison Nuwellis has a beta of 0.359, suggesting its less volatile than the S&P 500 by 64.091%.

Hologic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nuwellis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hologic pays -- of its earnings as a dividend. Nuwellis pays out -- of its earnings as a dividend.

Hologic quarterly revenues are $1B, which are larger than Nuwellis quarterly revenues of $2.3M. Hologic's net income of $201M is higher than Nuwellis's net income of -$1.5M. Notably, Hologic's price-to-earnings ratio is 19.52x while Nuwellis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic is 3.61x versus 0.21x for Nuwellis. Usually stocks with elevated PS ratios are considered overvalued.

Quanterix has a net margin of 19.67% compared to Hologic's net margin of -34.09%. Hologic's return on equity of 15.28% beat Quanterix's return on equity of -11.35%.

Hologic has a consensus price target of $78.66, signalling upside risk potential of 27.09%. On the other hand Quanterix has an analysts' consensus of $14.50 which suggests that it could grow by 101.67%. Given that Quanterix has higher upside potential than Hologic, analysts believe Quanterix is more attractive than Hologic.

Hologic has a beta of 0.971, which suggesting that the stock is 2.862% less volatile than S&P 500. In comparison Quanterix has a beta of 1.336, suggesting its more volatile than the S&P 500 by 33.57%.

Hologic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quanterix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hologic pays -- of its earnings as a dividend. Quanterix pays out -- of its earnings as a dividend.

Hologic quarterly revenues are $1B, which are larger than Quanterix quarterly revenues of $34.1M. Hologic's net income of $201M is higher than Quanterix's net income of -$11.6M. Notably, Hologic's price-to-earnings ratio is 19.52x while Quanterix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic is 3.61x versus 2.04x for Quanterix. Usually stocks with elevated PS ratios are considered overvalued.

Steris PLC has a net margin of 19.67% compared to Hologic's net margin of 12.66%. Hologic's return on equity of 15.28% beat Steris PLC's return on equity of 7.27%.

Hologic has a consensus price target of $78.66, signalling upside risk potential of 27.09%. On the other hand Steris PLC has an analysts' consensus of $250.13 which suggests that it could grow by 12.16%. Given that Hologic has higher upside potential than Steris PLC, analysts believe Hologic is more attractive than Steris PLC.

Hologic has a beta of 0.971, which suggesting that the stock is 2.862% less volatile than S&P 500. In comparison Steris PLC has a beta of 0.919, suggesting its less volatile than the S&P 500 by 8.088%.

Hologic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Steris PLC offers a yield of 1% to investors and pays a quarterly dividend of $0.57 per share. Hologic pays -- of its earnings as a dividend. Steris PLC pays out 53.03% of its earnings as a dividend. Steris PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hologic quarterly revenues are $1B, which are smaller than Steris PLC quarterly revenues of $1.4B. Hologic's net income of $201M is higher than Steris PLC's net income of $173.5M. Notably, Hologic's price-to-earnings ratio is 19.52x while Steris PLC's PE ratio is 47.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic is 3.61x versus 4.10x for Steris PLC. Usually stocks with elevated PS ratios are considered overvalued.

Varex Imaging has a net margin of 19.67% compared to Hologic's net margin of -0.15%. Hologic's return on equity of 15.28% beat Varex Imaging's return on equity of -8.27%.

Hologic has a consensus price target of $78.66, signalling upside risk potential of 27.09%. On the other hand Varex Imaging has an analysts' consensus of $21.20 which suggests that it could grow by 68.66%. Given that Varex Imaging has higher upside potential than Hologic, analysts believe Varex Imaging is more attractive than Hologic.

Hologic has a beta of 0.971, which suggesting that the stock is 2.862% less volatile than S&P 500. In comparison Varex Imaging has a beta of 0.563, suggesting its less volatile than the S&P 500 by 43.729%.

Hologic has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Varex Imaging offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hologic pays -- of its earnings as a dividend. Varex Imaging pays out -- of its earnings as a dividend.

Hologic quarterly revenues are $1B, which are larger than Varex Imaging quarterly revenues of $199.8M. Hologic's net income of $201M is higher than Varex Imaging's net income of -$300K. Notably, Hologic's price-to-earnings ratio is 19.52x while Varex Imaging's PE ratio is 17.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hologic is 3.61x versus 0.63x for Varex Imaging. Usually stocks with elevated PS ratios are considered overvalued.